Multiple endocrine neoplasia (MEN) syndromes are a group of rare autosomal dominant hereditary disorders that are classified into 5 distinct types. MEN2A, the most common type of MEN2, is associated with mutations and variants of RET, which are continually being updated. However, studies regarding RET mutations/variants related to MEN2A in the Chinese population are scarce, and patients involving MEN2A along with other differentiated thyroid tumors are rarer. We report a 54-year-old Chinese woman diagnosed with MEN2A and multiple follicular-derived thyroid tumors. Ultrasonography and computed tomography revealed a nodule in the thyroid and a nodule in the left adrenal gland. Laboratory investigations revealed elevated levels of both calcitonin and parathyroid hormone. The patient also had an 8-year history of hypertension, which normalized following the adrenal mass resection. Pathology identified 3 types of thyroid tumors and one type of adrenal tumor: the thyroid tumors consisted of medullary thyroid carcinoma, follicular adenoma, and papillary thyroid carcinoma, while the adrenal tumor was pheochromocytoma. Whole exome sequencing identified multiple germline mutations in the RET proto-oncogene, specifically R114H, A432A, and G691S. This report suggests that RET variants in MEN2A patients from the Chinese population may differ from the common RET variants. Additionally, MEN2A patients may present with thyroid follicular epithelial-derived tumors; however, further studies are necessary to determine any potential associations with RET variants.
McDonnellJEGildMLClifton-BlighRJ, et al.Multiple endocrine neoplasia: an update. Intern Med J. 2019;49(8):954–961.
2.
NoséVGillATeijeiroJMC, et al.Overview of the 2022 WHO classification of familial endocrine tumor syndromes. Endocr Pathol. 2022;33(1):197–227.
3.
MathiesenJSEffraimidisGRossingM, et al.Multiple endocrine neoplasia type 2: a review. Semin Cancer Biol. 2022;79:163‐179. DOI: 10.1016/j.semcancer.2021.03.035.
4.
WellsSAAsaSLDralleH, et al.Revised American Thyroid Association Guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25(6):567–610.
5.
JayasingheRBasnayakeOJayarajahU, et al.Management of medullary carcinoma of the thyroid: a review. J Int Med Res. 2022;50(7):1–20.
6.
MachensALorenzKSekullaC, et al.Molecular epidemiology of multiple endocrine neoplasia 2: implications for RET screening in the new millenium. Eur J Endocrinol. 2013;168(3):307–314.
7.
MathiesenJSKroustrupJPVestergaardP, et al.Incidence and prevalence of multiple endocrine neoplasia 2A in Denmark 1901–2014: a nationwide study. Clin Epidemiol. 2018(10):1479–1487.
8.
ZnaczkoADonnellyDEMorrisonPJ. Epidemiology, clinical features, and genetics of multiple endocrine neoplasia type 2B in a complete population. Oncologist. 2014;19(12):1284–1286.
9.
IshizakaYItohFTahiraT, et al.Human ret proto-oncogene mapped to chromosome 10q11.2. Oncogene. 1989;4(12):1519–1521.
10.
SimpsonNEKiddKKGoodfellowPJ, et al.Assignment of multiple endocrine neoplasia type 2A to chromosome 10 by linkage. Nature. 1987;328(6130):528–530.
11.
SchuchardtAD'AgatiVLarsson-BlombergL, et al.Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. Nature. 1994;367(6461):380–383.
12.
AsaiNFukudaTWuZ, et al.Targeted mutation of serine 697 in the Ret tyrosine kinase causes migration defect of enteric neural crest cells. Development (Cambridge, England). 2006;133(22):4507–4516.
13.
JainSKnotenAHoshiM, et al.Organotypic specificity of key RET adaptor-docking sites in the pathogenesis of neurocristopathies and renal malformations in mice. J Clin Invest. 2010;120(3):778–790.
14.
TaïebDKebebewECastinettiF, et al.Diagnosis and preoperative imaging of multiple endocrine neoplasia type 2: current status and future directions. Clin Endocrinol (Oxf). 2014;81(3):317–328.
15.
GriecoMSantoroMBerlingieriMT, et al.PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell. 1990;60(4):557–563.
16.
SalvatoreDSantoroMSchlumbergerM. The importance of the RET gene in thyroid cancer and therapeutic implications. Nat Rev Endocrinol. 2021;17(5):296–306.
17.
UnderdahlLOWoolnerLBBlackBM. Multiple endocrine adenomas; report of 8 cases in which the parathyroids, pituitary and pancreatic islets were involved. J Clin Endocrinol Metab. 1953;13(1):20–47.
18.
CatalonaWJEngelmanKKetchamAS, et al.Familial medullary thyroid carcinoma, pheochromocytoma, and parathyroid adenoma (Sipple's syndrome). Study of a kindred. Cancer. 1971;28(5):1245–1254.
19.
SteinerALGoodmanADPowersSR. Study of a kindred with pheochromocytoma, medullary thyroid carcinoma, hyperparathyroidism and Cushing's disease: multiple endocrine neoplasia, type 2. Medicine (Baltimore). 1968;47(5):371–409.
20.
Frank-RaueKRybickiLAErlicZ, et al.Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10. Hum Mutat. 2011;32(1):51–58.
21.
EliseiRTacitoARamoneT, et al.Twenty-five years experience on RET genetic screening on hereditary MTC: an update on the prevalence of germline RET mutations. Genes (Basel). 2019;10(9):698.
22.
MacielRMBCamachoCPAssumpçãoLVM, et al.Genotype and phenotype landscape of MEN2 in 554 medullary thyroid cancer patients: the BrasMEN study. Endocr Connect. 2019;8(3):289–298.
23.
LebeaultMPinsonSGuillaud-BatailleM, et al.Nationwide French study of RET variants detected from 2003 to 2013 suggests a possible influence of polymorphisms as modifiers. Thyroid. 2017;27(12):1511–1522.
24.
CaiJLiLYeL, et al.Exome sequencing reveals mutant genes with low penetrance involved in MEN2A-associated tumorigenesis. Endocr Relat Cancer. 2015;22(1):23–33.
25.
QiXPZhaoJQFangXD, et al.Spectrum of germline RET variants identified by targeted sequencing and associated multiple endocrine neoplasia type 2 susceptibility in China. BMC Cancer. 2021;21(1):369.
26.
SiqueiraDRCeolinLFerreiraCV, et al.Role of RET genetic variants in MEN2-associated pheochromocytoma. Eur J Endocrinol. 2014;170(6):821–828.
27.
MishraVKowtalPRaneP, et al.Genetic risk association of CDKN1A and RET gene SNPs with medullary thyroid carcinoma: results from the largest MTC cohort and meta-analysis. Cancer Med. 2019;8(13):6151–6161.
28.
RichardsSAzizNBaleS, et al.Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–424.
29.
Garcia-BarcelóMShamMHLeeWS, et al.Highly recurrent RET mutations and novel mutations in genes of the receptor tyrosine kinase and endothelin receptor B pathways in Chinese patients with sporadic Hirschsprung disease. Clin Chem. 2004;50(1):93–100.
30.
CornesBKTangCSLeonTY, et al.Haplotype analysis reveals a possible founder effect of RET mutation R114H for Hirschsprung's disease in the Chinese population. PloS one. 2010;5(6):e10918.
31.
NgoDNSoMTGuiH, et al.Screening of the RET gene of Vietnamese Hirschsprung patients identifies 2 novel missense mutations. J Pediatr Surg. 2012;47(10):1859–1864.
32.
LesueurFCebrianARobledoM, et al.Polymorphisms in RET and its coreceptors and ligands as genetic modifiers of multiple endocrine neoplasia type 2A. Cancer Res. 2006;66(2):1177–1180.
33.
RobledoMGilLPollánM, et al.Polymorphisms G691S/S904S of RET as genetic modifiers of MEN 2A. Cancer Res. 2003;63(8):1814–1817.
34.
ColomboCMinnaERizzettiMG, et al.The modifier role of RET-G691S polymorphism in hereditary medullary thyroid carcinoma: functional characterization and expression/penetrance studies. Orphanet J Rare Dis. 2015;10:25.
35.
EliseiRCosciBRomeiC, et al.RET Exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population. J Clin Endocrinol Metab. 2004;89(7):3579–3584.
36.
Cardot-BautersCLeteurtreELeclercL, et al.Does the RET variant G691S influence the features of sporadic medullary thyroid carcinoma?. Clin Endocrinol (Oxf). 2008;69(3):506–510.
37.
CeolinLSiqueiraDRFerreiraCV, et al.Additive effect of RET polymorphisms on sporadic medullary thyroid carcinoma susceptibility and tumor aggressiveness. Eur J Endocrinol. 2012;166(5):847–854.
38.
MachensAFrank-RaueKLorenzK, et al.Clinical relevance of RET variants G691S, L769L, S836S and S904S to sporadic medullary thyroid cancer. Clin Endocrinol (Oxf). 2012;76(5):691–697.
39.
FernándezRMPeciñaAAntiñoloG, et al.Analysis of RET polymorphisms and haplotypes in the context of sporadic medullary thyroid carcinoma. Thyroid. 2006;16(4):411–417.
40.
RashidFAKhanMSTabassumS, et al.Discrepancies of RET gene and risk of differentiated thyroid carcinoma. Cancer Biomarkers: Section A of Disease Markers. 2022;33(1):111–121.
41.
LönnSBhattiPAlexanderBH, et al.Papillary thyroid cancer and polymorphic variants in TSHR- and RET-related genes: a nested case-control study within a cohort of U.S. radiologic technologists. Cancer Epidemiol Biomarkers Prev. 2007;16(1):174–177.
42.
SantosMAzevedoTMartinsT, et al.Association of RET genetic polymorphisms and haplotypes with papillary thyroid carcinoma in the Portuguese population: a case-control study. PloS one. 2014;9(10):e109822.
